- ISIN
- US3596161097
- CUSIP
- 359616109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 18, 2019
Highlights
- Market Cap
- $245.41M
- Enterprise Value
- $203.48M
- EPS (TTM)
- -$1.15
- EBITDA (TTM)
- -$78.37M
- Year Range
- $2.83 - $15.74
- Target Price
- $20.67
- ROA (TTM)
- -21.95%
- ROE (TTM)
- -22.84%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
FULC Performance Chart
Fulcrum Therapeutics, Inc. (FULC) is down 71.5% since the beginning of the year. At $3 per share, FULC is trading 79.5% below its 52-week high of $16. Investors who bought $1,000 worth of FULC shares 5 years ago would now be looking at an investment worth $368.
Loading charts...
Returns By Period
Fulcrum Therapeutics, Inc. (FULC) has returned -71.53% so far this year and -54.23% over the past 12 months.
Fulcrum Therapeutics, Inc.
- 1D
- 2.55%
- 1M
- -54.13%
- YTD
- -71.53%
- 6M
- -64.46%
- 1Y
- -54.23%
- 3Y*
- 1.60%
- 5Y*
- -18.10%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
FULC Monthly Returns History
Based on dividend-adjusted daily data since Jul 18, 2019, FULC's average daily return is +0.16%, while the average monthly return is +5.45%. At this rate, an investment would double in approximately 1.1 years.
Historically, 48% of months were positive and 52% were negative. The best month was Aug 2021 with a return of +306.3%, while the worst month was Apr 2022 at -59.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.
On a daily basis, FULC closed higher 48% of trading days. The best single day was Aug 10, 2021 with a return of +125.3%, while the worst single day was Sep 12, 2024 at -61.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.13% | -21.90% | -8.47% | -7.04% | -2.95% | -53.47% | -71.53% | ||||||
| 2025 | -15.74% | -9.34% | -19.78% | 33.68% | 78.57% | 0.07% | -2.18% | -3.71% | 41.98% | -4.89% | 25.03% | 3.38% | 140.64% |
| 2024 | 6.96% | 41.41% | -7.54% | -24.47% | 10.10% | -21.02% | 49.68% | -7.87% | -58.25% | -11.48% | 21.84% | 22.08% | -30.37% |
| 2023 | 73.21% | -52.10% | -52.81% | -12.28% | 8.80% | 21.32% | 15.76% | 44.76% | -19.71% | -18.02% | 31.87% | 40.62% | -7.28% |
| 2022 | -31.26% | -9.54% | 115.00% | -59.32% | -25.99% | -31.18% | 20.00% | 25.85% | 9.32% | -31.27% | 23.20% | 6.28% | -58.85% |
| 2021 | -5.55% | 14.01% | -6.58% | -4.50% | -20.62% | 17.36% | -30.25% | 306.29% | -5.02% | -21.52% | -34.51% | 22.00% | 51.07% |
Benchmark Metrics
Fulcrum Therapeutics, Inc. has an annualized alpha of 19.75%, beta of 1.51, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since July 19, 2019.
- This stock participated in 218.22% of S&P 500 Index downside but only 144.28% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 19.75%
- Beta
- 1.51
- R²
- 0.07
- Upside Capture
- 144.28%
- Downside Capture
- 218.22%
Return for Risk
Risk / Return Rank
FULC ranks 16 for risk / return — in the bottom 16% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Fulcrum Therapeutics, Inc. (FULC) and compare them to S&P 500 Index.
| FULC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.79 | ||
| Sortino ratioReturn per unit of downside risk | -3.41 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.41 | -0.46 |
| Calmar ratioReturn relative to maximum drawdown | -0.69 | 2.93 | -3.62 |
| Martin ratioReturn relative to average drawdown | -1.81 | 13.52 | -15.33 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Fulcrum Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Fulcrum Therapeutics, Inc. was 92.70%, occurring on Apr 12, 2023. The portfolio has not yet recovered.
The current Fulcrum Therapeutics, Inc. drawdown is 89.60%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -92.70%Apr 2023 | 1y 6mo | — | 4y 8moSep 2021 - now |
2019 bear market2019 | -70.05%Oct 2019 | 2mo 23d | 1mo 5d | 3mo 28dJul 2019 - Nov 2019 |
2020 bear market2020 | -67.27%Aug 2020 | 2mo 3d | 11mo 19d | 1y 1moJun 2020 - Aug 2021 |
COVID crash2020 | -57.15%Apr 2020 | 2mo 20d | 2mo 23d | 5mo 13dJan 2020 - Jun 2020 |
2019 bear market2019 | -26.98%Dec 2019 | 9d | 18d | 27dNov 2019 - Dec 2019 |
Drawdown Indicators
| FULC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.70% | -56.78% | -35.92% |
Max Drawdown (1Y)Largest decline over 1 year | -78.49% | -9.10% | -69.39% |
Max Drawdown (3Y)Largest decline over 3 years | -79.08% | -18.90% | -60.18% |
Max Drawdown (5Y)Largest decline over 5 years | -92.70% | -25.43% | -67.27% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -89.60% | -0.74% | -88.86% |
Average DrawdownAverage peak-to-trough decline | -62.65% | -10.72% | -51.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.01% | 1.97% | +28.04% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Fulcrum Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Fulcrum Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for FULC in comparison with other companies in the Biotechnology industry. Currently, FULC has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with FULC
Add Fulcrum Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with FULC